• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.

作者信息

Kearns Pamela, Zwaan Christian M, Reinhardt Dirk, Gibson Brenda, Moreno Lucas, Nysom Karsten, Nakahara Susumu, Huang Fei, Zhou Wangda, Parasrampuria Dolly A, Nemat Sepideh

机构信息

NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.

Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.

出版信息

Br J Haematol. 2019 Aug;186(3):e7-e11. doi: 10.1111/bjh.15847. Epub 2019 Mar 7.

DOI:10.1111/bjh.15847
PMID:30847896
Abstract
摘要

相似文献

1
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.地西他滨与阿糖胞苷序贯给药用于复发或难治性急性髓性白血病儿童的1-2期安全性、疗效及药代动力学研究
Br J Haematol. 2019 Aug;186(3):e7-e11. doi: 10.1111/bjh.15847. Epub 2019 Mar 7.
2
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.地西他滨、伊达比星、阿糖胞苷和粒细胞集落刺激因子联合（DIAG）方案治疗高危骨髓增生异常综合征和急性髓系白血病。
Ann Hematol. 2019 Sep;98(9):2223-2225. doi: 10.1007/s00277-019-03674-2. Epub 2019 Apr 12.
3
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.地西他滨联合阿克拉霉素/阿糖胞苷治疗难治性急性髓系白血病的临床疗效。
Ann Hematol. 2012 Dec;91(12):1879-86. doi: 10.1007/s00277-012-1550-y. Epub 2012 Aug 16.
4
Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.地西他滨诱导化疗后血小板计数的早期恢复是老年新发急性髓系白血病患者对治疗反应良好的预后标志物。
BMC Cancer. 2018 Dec 19;18(1):1269. doi: 10.1186/s12885-018-5160-5.
5
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.考洛菲兰、高剂量阿糖胞苷和脂质体柔红霉素治疗儿科复发/难治性急性髓系白血病的初步研究
Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17.
6
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.与传统化疗相比，在高危骨髓肿瘤中，先用地西他滨进行表观遗传启动，再给予低剂量伊达比星/阿糖胞苷，具有增强的抗白血病作用。
Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931. Epub 2015 Oct 13.
7
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.伏沙罗辛联合阿糖胞苷对比安慰剂联合阿糖胞苷治疗初治复发或难治性急性髓系白血病患者（VALOR）：一项随机、对照、双盲、多中心3期研究
Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.
8
Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.微小残留病可能是接受基于地西他滨的化疗诱导的新诊断急性髓系白血病患者的早期预后指标。
Hematology. 2019 Dec;24(1):552-558. doi: 10.1080/16078454.2019.1642552.
9
Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.低剂量阿糖胞苷和低甲基化药物用于唐氏综合征合并急性髓系白血病的治疗
Pediatr Blood Cancer. 2024 Jun;71(6):e30974. doi: 10.1002/pbc.30974. Epub 2024 Mar 24.
10
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.一项关于新型口服PLK1抑制剂奥万塞替布用于复发或难治性急性髓系白血病患者联合治疗的Ib期研究。
Clin Cancer Res. 2020 Dec 1;26(23):6132-6140. doi: 10.1158/1078-0432.CCR-20-2586. Epub 2020 Sep 30.

引用本文的文献

1
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed -rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.阿扎胞苷作为化疗的表观遗传启动剂，对于新诊断的重排急性淋巴细胞白血病婴儿是安全且耐受性良好的：儿童肿瘤学组试验AALL15P1。
Haematologica. 2024 Dec 1;109(12):3918-3927. doi: 10.3324/haematol.2024.285158.
2
A novel biocompatible Eu-based coordination polymers of cytarabine anticancer drug: Preparation, luminescence properties and anticancer activity studies.一种新型阿糖胞苷抗癌药物的生物相容性铕基配位聚合物：制备、发光性质及抗癌活性研究
Front Chem. 2022 Nov 11;10:1043810. doi: 10.3389/fchem.2022.1043810. eCollection 2022.
3
Decitabine mildly attenuates -rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo-sensitizer.
地西他滨在体内可轻度减轻重排型急性淋巴细胞白血病，且是一种效果不佳的化疗增敏剂。
EJHaem. 2020 Aug 24;1(2):527-536. doi: 10.1002/jha2.81. eCollection 2020 Nov.